A PYMNTS Company

US/UK: Pharma M&A spree persists with latest deal

By  |  July 8, 2014

As the world’s pharmaceutical industry continues its recent spree of mergers and acquisitions, the consolidation seems to continue with AbbVie’s latest attempt to acquire one of its competitors.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The US pharmaceutical firm just raised its offer to purchase UK-based rival Shire to about $51 billion after an earlier offer was rejected. Reports say the initial bid amounted to about $46 billion.

    AbbVie is reportedly looking to purchase the UK firm to reduce its tax burden and shift its finances overseas. AbbVie is also seeking out its next business ventures as its top-selling product, Humira, is set to lose its patent protection in 2016. Humira accounts for nearly 60 percent of the company’s revenue, reports say, and is the world’s top selling drug.

    Full content: CNBC

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.